Lipid Nanoparticle-Encapsulated TALEN-Encoding mRNA Inactivates Hepatitis B Virus Replication in Cultured Cells and Transgenic Mice
Viruses · 2025
DOI: 10.3390/v17081090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Tiffany Smith und 7 weiteren Autor:innen. Beteiligte Einrichtung: Wits/SAMRC Antiviral Gene Therapy Research Unit, Infectious Diseases and Oncology Research Institute (IDORI), School of Pathology, Faculty of Health …. Hauptthemen laut MEDLINE: Hepatitis B virus, Virus Replication, RNA, Messenger, Nanoparticles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Poliomyelitis Research Foundation, South African Medial Research Council, South African National Research Council.
Abstract (Originalsprache)
Chronic infection with the hepatitis B virus (HBV) results in over 1 million deaths annually. Although currently licensed treatments, including pegylated interferon-α and nucleoside/nucleotide analogs, can inhibit viral replication, they rarely eradicate covalently closed circular DNA (cccDNA) reservoirs. Moreover, vaccination does not offer therapeutic benefit to already infected individuals or non-responders. Consequently, chronic infection is maintained by the persistence of cccDNA in infected hepatocytes. For this reason, novel therapeutic strategies that permanently inactivate cccDNA are a priority. Obligate heterodimeric transcription activator-like effector nucleases (TALENs) provide the precise gene-editing needed to disable cccDNA. To develop this strategy using a therapeutically relevant approach, TALEN-encoding mRNA targeting viral core and surface genes was synthesized using in vitro transcription with co-transcriptional capping. TALENs reduced hepatitis B surface antigen (HBsAg) by 80% in a liver-derived mammalian cell culture model of infection. In a stringent HBV transgenic murine model, a single dose of hepatotropic lipid nanoparticle-encapsulated TALEN mRNA lowered HBsAg by 63% and reduced viral particle equivalents by more than 99%, without evidence of toxicity. A surveyor assay demonstrated mean in vivo HBV DNA mutation rates of approximately 16% and 15% for Core and Surface TALENs, respectively. This study presents the first evidence of the therapeutic potential of TALEN-encoding mRNA to inactivate HBV replication permanently.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wits/SAMRC Antiviral Gene Therapy Research Unit, Infectious Diseases and Oncology Research Institute (IDORI), School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Parktown 2193, South Africa.
ORCID-Profile: Kristie Bloom, Mohube Betty Maepa, Abdullah Ely, Patrick Arbuthnot
Förderung
- Poliomyelitis Research Foundation
- South African Medial Research Council
- South African National Research Council
Zitieren
APA
Smith, T., Singh, P., Bhana, R., Kairuz, D., Bloom, K., Maepa, M. B., Ely, A., & Arbuthnot, P. (2025). Lipid Nanoparticle-Encapsulated TALEN-Encoding mRNA Inactivates Hepatitis B Virus Replication in Cultured Cells and Transgenic Mice. Viruses. https://doi.org/10.3390/v17081090
Vancouver
Smith T, Singh P, Bhana R, Kairuz D, Bloom K, Maepa MB, et al. Lipid Nanoparticle-Encapsulated TALEN-Encoding mRNA Inactivates Hepatitis B Virus Replication in Cultured Cells and Transgenic Mice. Viruses. 2025. doi:10.3390/v17081090
BibTeX
@article{Smith2025,
author = {Smith, Tiffany and Singh, Prashika and Bhana, Ridhwaanah and Kairuz, Dylan and Bloom, Kristie and Maepa, Mohube Betty and Ely, Abdullah and Arbuthnot, Patrick},
title = {Lipid Nanoparticle-Encapsulated TALEN-Encoding mRNA Inactivates Hepatitis B Virus Replication in Cultured Cells and Transgenic Mice},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17081090}
}
EUVIMED